Table 1.
Baseline and follow-up characteristics of the PLHIV initiating ART by age (N=73,525)
| Age (years)
|
Total N=73,525 | |||||
|---|---|---|---|---|---|---|
| 16–29 N=16,458 | 30–39 N=29,968 | 40–49 N=18,561 | 50–59 N=6,792 | ≥60 N=1,736 | ||
|
| ||||||
| Gender: female (%) | 86.3 | 68.6 | 51.1 | 47.8 | 50.9 | 65.8 |
| Initial clinical stage (%) | ||||||
| WHO I/II or CDC A | 40.6 | 37.1 | 33.9 | 34.8 | 35.4 | 36.8 |
| WHO III/IV or AIDS | 25.8 | 28.1 | 30.2 | 30.9 | 34.0 | 28.5 |
| Missing | 33.6 | 34.8 | 35.9 | 34.3 | 30.6 | 34.7 |
| Initial hemoglobin levela (g/dL) | 10.2 [9.0–11.5] | 10.5 [9.0–11.9] | 10.7 [9.1–12.0] | 10.7 [9.2–12.0] | 10.7 [9.3–11.9] | 10.5 [9.0–11.9] |
| Initial CD4 counta (cells/µL) | 185 [81–307] | 167 [71–278] | 160 [68–271] | 175 [84–287] | 182 [91–300] | 170 [74–284] |
| BMI (kg/m2) (%) | ||||||
| <18 | 12.7 | 10.5 | 10.2 | 10.7 | 10.8 | 11.0 |
| 18–24.9 | 31.0 | 32.5 | 32.0 | 32.5 | 29.0 | 32.0 |
| ≥25 | 7.2 | 9.5 | 10.4 | 10.1 | 8.9 | 9.2 |
| Missing | 49.0 | 47.5 | 47.4 | 46.7 | 51.3 | 47.8 |
| Year of ART initiation (%) | ||||||
| <2007 | 30.8 | 30.9 | 28.3 | 23.5 | 20.6 | 35.4 |
| 2007–2010 | 37.2 | 35.2 | 35.0 | 33.6 | 32.4 | 47.0 |
| 2011–2015 | 31.9 | 33.9 | 36.7 | 42.9 | 47.0 | 20.6 |
| Follow-up durationa (months) | 35.4 [9.8–76.5] | 39.5 [11.7–82.1] | 38.4 [11.5–81.0] | 33.3 [9.7–71.2] | 24.8 [10.8–79.1] | 37.2 [10.8–79.1] |
| Death at 36 months (%) | 3.7 | 3.9 | 4.7 | 5.9 | 6.9 | 4.3 |
| Number of events | 613 | 1,182 | 872 | 402 | 120 | 3,189 |
| LTFU at 36 months (%) | 33.8 | 28.4 | 26.6 | 26.5 | 31.5 | 29.0 |
| Number of events | 5,563 | 8,515 | 4,929 | 1,802 | 546 | 21,355 |
Note:
a
Median [IQR].
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CDC, Centers for Disease Control and Prevention; IQR, interquartile range; LTFU, lost to follow-up; PLHIV, people living with HIV; WHO, World Health Organization.